Drug Profile
Ampreloxetine - Theravance Biopharma
Alternative Names: Ampreloxetine; Ampreloxetine hydrochloride; TD 9855; TD-9855 HClLatest Information Update: 21 Nov 2023
Price :
$50
*
At a glance
- Originator Theravance
- Developer Theravance Biopharma
- Class Analgesics; Antihypotensives; Behavioural disorder therapies; Piperidines; Small molecules
- Mechanism of Action Adrenergic uptake inhibitors; Central nervous system stimulants; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Orthostatic hypotension
- Discontinued Attention-deficit hyperactivity disorder; Fibromyalgia
Most Recent Events
- 17 Nov 2023 Theravance Biopharma announces intention to submit NDA to US FDA for symptomatic neurogenic orthostatic hypotension
- 28 Aug 2023 Efficacy data from the phase III SEQUOIA trial in Orthostatic hypotension released by Theravance Biopharma
- 28 Aug 2023 Safety data from phase I trial in Orthostatic hypertension released by Theravance Biopharma